Received Mar 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 945656 | IM / LA |
Two Dose Series Completed, and Received A Third Dose; 1st Dose Given in Nov-2024, 2nd Dose given in Jan-2025; Initial report received on 12-Feb-2025. A pharmacist reported that a 25-year-old male received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization two months after the first and received a third dose of HEPLISAV-B. No medical history or concomitant medications were reported. On 20-Nov-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 945656, expiration date 24-Jan-2027, NDC# 43528-003-01) intramuscularly in the left arm. On 23-Jan-2025, 64 days after receiving dose 1 of HEPLISAV-B, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot # 945659, expiration date 31-Jan-2027, NDC# 43528-003-01) intramuscularly in the left arm. On 11-Feb-2025, 19 days after receiving dose 2 of HEPLISAV-B, the patient received dose 3 of a hepatitis B vaccine [HEPLISAV-B (lot # 945659, expiration date 31-Jan-2027, NDC# 43528-003-01) intramuscularly in the right arm. This was the third dose of HEPLISAV-B. No adverse effects were reported to any of the 3 doses the patient received. Company Comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.